Zugo-cel Update: Phase 2 Trial Advancement in Autoimmune Disease and Hematologic Malignancies

Today we shared an update on zugo-cel (formerly known as CTX112™) across autoimmune disease and hematologic malignancies. In autoimmune disease, early clinical experience demonstrates rapid B-cell depletion and initial signals of clinical improvement. In oncology, the data generated to date support the advancement of zugo-cel into the Phase 2 portion of the ongoing study. We look forward to sharing additional findings as the studies progress.

The FDA has approved imlunestrant for the treatment of adults with ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer with disease progression. It is indicated following at least one line of endocrine therapy. Additionally, Guardant360 CDx was approved as a companion diagnostic device to identify ideal candidates for treatment with this drug. #Breast_Cancer #ER_Positive #HER2_Negative

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Cancer treatment may save a life—but sometimes it leaves lasting pain behind. Chemotherapy-Induced Peripheral Neuropathy causes burning, numbness, and weakness that may persist long after cancer is gone. Patients often say: “I survived cancer… but I don’t feel normal anymore.” Pharmacists play a quiet role—monitoring neurotoxic drugs, adjusting doses, and validating pain that cannot be seen on scans. Survival is not the end of care. Quality of life matters too. Beating cancer doesn’t always end suffering. Chemotherapy-induced neuropathy reminds us why pharmacists matter beyond dispensing. #Pharmacy #OncologyPharmacy #PeripheralNeuropathy #CancerCare #MedicationSafety #PatientQualityOfLife

Are we any closer to a 'magic bullet' to eliminate cancer? 2025 was a year of wrap-ups. And on #theCancerNews, we wrapped up the year of oncology with a bow- highlighting top trends drawn from expert discussions at medical education conferences, oncologist interviews, and the most talked-about literature. • Is the Al-in-healthcare buzz all noise? • What classes of drugs topped FDA oncology approvals in 2025? • Beyond the US, what's going on with cancer care and delivery around the world? Check out the link below for answers and more, and stay tuned for several practice-changing research coverage as 2026 unfolds. https://lnkd.in/g94E3Uzf #2025oncologyupdates #cancercare #globaloncology #medicaladdvancements #thecancernews

SUN PHARMA Launches UNLOXCYT for CSCC Treatment Learn more & see why it matters 👇 https://lnkd.in/gb4qcUWJ "Patients with unresectable or metastatic CSCC now have a new and important treatment option to manage their disease... durable disease control and proven tolerability." - Ann W. Silk, MD, MS, Medical Oncologist at Dana-Farber Cancer Institute "UNLOXCYT is an evolution in checkpoint inhibition, combining durable efficacy with a proven tolerability profile..." - Richard Ascroft, CEO at Sun Pharma North America #SoHCNews

The current study provides insight into the associations between insulin and cancer, demonstrates and compares the prevalence of thyroid cancer among different cohorts with a spectrum of insulin resistance, including severe insulin resistance, type 2 diabetes, and euglycemic control groups. Read more: https://lnkd.in/gkVZ7v-T

The current study provides insight into the associations between insulin and cancer, demonstrates and compares the prevalence of thyroid cancer among different cohorts with a spectrum of insulin resistance, including severe insulin resistance, type 2 diabetes, and euglycemic control groups. Read more: https://lnkd.in/gkVZ7v-T

Loved presenting our work on EGFR inhibitor therapy in anal squamous cell carcinoma (ASCC) at GI ASCO 2026. Encouraging to see meaningful activity with acceptable toxicity, reinforcing the potential role of EGFR-targeted strategies—particularly in refractory and metastatic disease. Looking forward to further prospective and biomarker-driven studies. #GIASCO2026 #EGFR #ASCC #TargetedTherapy #OncologyResearch #MarshfieldClinic #Sanfordhealth

FDA News: The FDA has granted breakthrough therapy designation to T-DXd for the treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant systemic therapy and remain at high risk of recurrence. https://hubs.li/Q03YRmSf0